Rein Therapeutics, Inc. — Cash Flow Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Capital Allocation
How management deploys cash: investing in the business (Capex + M&A) vs returning to shareholders (Buybacks + Dividends).
Buybacks vs Stock-Based Comp
Cash Flow
Cash Flow by Activity
Operating Cash Flow↓-17.2% -$904K
$-6M
Free Cash Flow↓-17.2% -$904K
$-6M
Investing Cash Flow
$0
Financing Cash Flow↑+240400.0% +$2M
$2M
Capex
—
Stock-Based Comp↑+93.2% +$124K
$257K
D&A
$0
SBC Allocated Expense↑+93.2% +$124K
$257K
SBC Unrecognized Cost↑+305.7% +$2M
$2M